{"id":581,"date":"2023-09-19T14:31:00","date_gmt":"2023-09-19T14:31:00","guid":{"rendered":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?p=581"},"modified":"2023-11-03T14:36:22","modified_gmt":"2023-11-03T14:36:22","slug":"the-beta2%e2%80%90adrenergic-agonist-salbutamol-synergizes-with-paclitaxelon-cell-proliferation-and-tumor-growth-in-triple-negative-breast-cancermodels","status":"publish","type":"post","link":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?p=581","title":{"rendered":"The Beta2\u2010adrenergic agonist salbutamol synergizes with paclitaxelon cell proliferation and tumor growth in triple negative breast cancermodels"},"content":{"rendered":"\n<p class=\"has-text-align-left\">Martina Jablo\u00f1ski,<sup> <\/sup>Mar\u00eda Sol Rodr\u00edguez,\u00a0Ezequiel Mariano Rivero,\u00a0Carlos David Bruque,\u00a0Silvia Vanzulli,\u00a0Ariana Bruzzone,\u00a0Cecilia P\u00e9rez Pi\u00f1ero,\u00a0Isabel Alicia L\u00fcthy<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Abstract<\/h2>\n\n\n\n<p><strong>Purpose:&nbsp;<\/strong>Globally breast cancer accounts for 24.5% in incidence and 15.5% in cancer deaths in women. The triple-negative subtype lacks any specific therapy and is treated with chemotherapy, resulting in significant side-effects. We aimed to investigate if the dose of chemotherapeutic drugs could be diminished by co-administering it with the \u03b22-agonist salbutamol.<\/p>\n\n\n\n<div class=\"wp-block-buttons is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button has-custom-width wp-block-button__width-100\"><a class=\"wp-block-button__link wp-element-button\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37725114\/\" target=\"_blank\" rel=\"noreferrer noopener\">Ver Publicaci\u00f3n<\/a><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Martina Jablo\u00f1ski, Mar\u00eda Sol Rodr\u00edguez,\u00a0Ezequiel Mariano Rivero,\u00a0Carlos David Bruque,\u00a0Silvia Vanzulli,\u00a0Ariana Bruzzone,\u00a0Cecilia P\u00e9rez Pi\u00f1ero,\u00a0Isabel Alicia L\u00fcthy Abstract Purpose:&nbsp;Globally breast cancer accounts for 24.5% in incidence and 15.5% in cancer deaths in women. The triple-negative subtype lacks any specific therapy and is treated with chemotherapy, resulting in significant side-effects. We aimed to investigate if the dose of [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":518,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_eb_attr":"","_uag_custom_page_level_css":"","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[11],"tags":[],"class_list":["post-581","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publicaciones"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>The Beta2\u2010adrenergic agonist salbutamol synergizes with paclitaxelon cell proliferation and tumor growth in triple negative breast cancermodels - UCT HP<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?p=581\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Beta2\u2010adrenergic agonist salbutamol synergizes with paclitaxelon cell proliferation and tumor growth in triple negative breast cancermodels - UCT HP\" \/>\n<meta property=\"og:description\" content=\"Martina Jablo\u00f1ski, Mar\u00eda Sol Rodr\u00edguez,\u00a0Ezequiel Mariano Rivero,\u00a0Carlos David Bruque,\u00a0Silvia Vanzulli,\u00a0Ariana Bruzzone,\u00a0Cecilia P\u00e9rez Pi\u00f1ero,\u00a0Isabel Alicia L\u00fcthy Abstract Purpose:&nbsp;Globally breast cancer accounts for 24.5% in incidence and 15.5% in cancer deaths in women. The triple-negative subtype lacks any specific therapy and is treated with chemotherapy, resulting in significant side-effects. We aimed to investigate if the dose of [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?p=581\" \/>\n<meta property=\"og:site_name\" content=\"UCT HP\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-19T14:31:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-11-03T14:36:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/wp-content\/uploads\/2023\/10\/springer.png\" \/>\n\t<meta property=\"og:image:width\" content=\"250\" \/>\n\t<meta property=\"og:image:height\" content=\"200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Mirtha\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mirtha\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?p=581#article\",\"isPartOf\":{\"@id\":\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?p=581\"},\"author\":{\"name\":\"Mirtha\",\"@id\":\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/#\/schema\/person\/cb3d81609139435146e1257936dc9b98\"},\"headline\":\"The Beta2\u2010adrenergic agonist salbutamol synergizes with paclitaxelon cell proliferation and tumor growth in triple negative breast cancermodels\",\"datePublished\":\"2023-09-19T14:31:00+00:00\",\"dateModified\":\"2023-11-03T14:36:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?p=581\"},\"wordCount\":100,\"publisher\":{\"@id\":\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/#organization\"},\"image\":{\"@id\":\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?p=581#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/wp-content\/uploads\/2023\/10\/springer.png\",\"articleSection\":[\"publicaciones\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?p=581\",\"url\":\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?p=581\",\"name\":\"The Beta2\u2010adrenergic agonist salbutamol synergizes with paclitaxelon cell proliferation and tumor growth in triple negative breast cancermodels - UCT HP\",\"isPartOf\":{\"@id\":\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?p=581#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?p=581#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/wp-content\/uploads\/2023\/10\/springer.png\",\"datePublished\":\"2023-09-19T14:31:00+00:00\",\"dateModified\":\"2023-11-03T14:36:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?p=581#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?p=581\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?p=581#primaryimage\",\"url\":\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/wp-content\/uploads\/2023\/10\/springer.png\",\"contentUrl\":\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/wp-content\/uploads\/2023\/10\/springer.png\",\"width\":250,\"height\":200,\"caption\":\"springer\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?p=581#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The Beta2\u2010adrenergic agonist salbutamol synergizes with paclitaxelon cell proliferation and tumor growth in triple negative breast cancermodels\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/#website\",\"url\":\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/\",\"name\":\"UCT HP\",\"description\":\"Unidad de Conocimiento Traslacional Hospitalaria Patag\u00f3nica\",\"publisher\":{\"@id\":\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/#organization\"},\"alternateName\":\"Unidad de Conocimiento Traslacional Hospitalaria Patag\u00f3nica\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/#organization\",\"name\":\"UNIDAD DE CONOCIMIENTO TRASLACIONAL HOSPITALARIA PATAG\u00d3NICA\",\"alternateName\":\"UCTHP\",\"url\":\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/wp-content\/uploads\/2023\/10\/logo-UCT-HP.png\",\"contentUrl\":\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/wp-content\/uploads\/2023\/10\/logo-UCT-HP.png\",\"width\":1191,\"height\":357,\"caption\":\"UNIDAD DE CONOCIMIENTO TRASLACIONAL HOSPITALARIA PATAG\u00d3NICA\"},\"image\":{\"@id\":\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/#\/schema\/person\/cb3d81609139435146e1257936dc9b98\",\"name\":\"Mirtha\",\"url\":\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?author=2\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The Beta2\u2010adrenergic agonist salbutamol synergizes with paclitaxelon cell proliferation and tumor growth in triple negative breast cancermodels - UCT HP","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?p=581","og_locale":"es_ES","og_type":"article","og_title":"The Beta2\u2010adrenergic agonist salbutamol synergizes with paclitaxelon cell proliferation and tumor growth in triple negative breast cancermodels - UCT HP","og_description":"Martina Jablo\u00f1ski, Mar\u00eda Sol Rodr\u00edguez,\u00a0Ezequiel Mariano Rivero,\u00a0Carlos David Bruque,\u00a0Silvia Vanzulli,\u00a0Ariana Bruzzone,\u00a0Cecilia P\u00e9rez Pi\u00f1ero,\u00a0Isabel Alicia L\u00fcthy Abstract Purpose:&nbsp;Globally breast cancer accounts for 24.5% in incidence and 15.5% in cancer deaths in women. The triple-negative subtype lacks any specific therapy and is treated with chemotherapy, resulting in significant side-effects. We aimed to investigate if the dose of [&hellip;]","og_url":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?p=581","og_site_name":"UCT HP","article_published_time":"2023-09-19T14:31:00+00:00","article_modified_time":"2023-11-03T14:36:22+00:00","og_image":[{"width":250,"height":200,"url":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/wp-content\/uploads\/2023\/10\/springer.png","type":"image\/png"}],"author":"Mirtha","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Mirtha"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?p=581#article","isPartOf":{"@id":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?p=581"},"author":{"name":"Mirtha","@id":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/#\/schema\/person\/cb3d81609139435146e1257936dc9b98"},"headline":"The Beta2\u2010adrenergic agonist salbutamol synergizes with paclitaxelon cell proliferation and tumor growth in triple negative breast cancermodels","datePublished":"2023-09-19T14:31:00+00:00","dateModified":"2023-11-03T14:36:22+00:00","mainEntityOfPage":{"@id":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?p=581"},"wordCount":100,"publisher":{"@id":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/#organization"},"image":{"@id":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?p=581#primaryimage"},"thumbnailUrl":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/wp-content\/uploads\/2023\/10\/springer.png","articleSection":["publicaciones"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?p=581","url":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?p=581","name":"The Beta2\u2010adrenergic agonist salbutamol synergizes with paclitaxelon cell proliferation and tumor growth in triple negative breast cancermodels - UCT HP","isPartOf":{"@id":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?p=581#primaryimage"},"image":{"@id":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?p=581#primaryimage"},"thumbnailUrl":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/wp-content\/uploads\/2023\/10\/springer.png","datePublished":"2023-09-19T14:31:00+00:00","dateModified":"2023-11-03T14:36:22+00:00","breadcrumb":{"@id":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?p=581#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ucthp.hospitalelcalafate.gob.ar\/?p=581"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?p=581#primaryimage","url":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/wp-content\/uploads\/2023\/10\/springer.png","contentUrl":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/wp-content\/uploads\/2023\/10\/springer.png","width":250,"height":200,"caption":"springer"},{"@type":"BreadcrumbList","@id":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?p=581#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/"},{"@type":"ListItem","position":2,"name":"The Beta2\u2010adrenergic agonist salbutamol synergizes with paclitaxelon cell proliferation and tumor growth in triple negative breast cancermodels"}]},{"@type":"WebSite","@id":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/#website","url":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/","name":"UCT HP","description":"Unidad de Conocimiento Traslacional Hospitalaria Patag\u00f3nica","publisher":{"@id":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/#organization"},"alternateName":"Unidad de Conocimiento Traslacional Hospitalaria Patag\u00f3nica","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/#organization","name":"UNIDAD DE CONOCIMIENTO TRASLACIONAL HOSPITALARIA PATAG\u00d3NICA","alternateName":"UCTHP","url":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/#\/schema\/logo\/image\/","url":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/wp-content\/uploads\/2023\/10\/logo-UCT-HP.png","contentUrl":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/wp-content\/uploads\/2023\/10\/logo-UCT-HP.png","width":1191,"height":357,"caption":"UNIDAD DE CONOCIMIENTO TRASLACIONAL HOSPITALARIA PATAG\u00d3NICA"},"image":{"@id":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/#\/schema\/person\/cb3d81609139435146e1257936dc9b98","name":"Mirtha","url":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?author=2"}]}},"author_meta":{"display_name":"Mirtha","author_link":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?author=2"},"featured_img":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/wp-content\/uploads\/2023\/10\/springer.png","uagb_featured_image_src":{"full":["https:\/\/ucthp.hospitalelcalafate.gob.ar\/wp-content\/uploads\/2023\/10\/springer.png",250,200,false],"thumbnail":["https:\/\/ucthp.hospitalelcalafate.gob.ar\/wp-content\/uploads\/2023\/10\/springer-150x150.png",150,150,true],"medium":["https:\/\/ucthp.hospitalelcalafate.gob.ar\/wp-content\/uploads\/2023\/10\/springer.png",250,200,false],"medium_large":["https:\/\/ucthp.hospitalelcalafate.gob.ar\/wp-content\/uploads\/2023\/10\/springer.png",250,200,false],"large":["https:\/\/ucthp.hospitalelcalafate.gob.ar\/wp-content\/uploads\/2023\/10\/springer.png",250,200,false],"1536x1536":["https:\/\/ucthp.hospitalelcalafate.gob.ar\/wp-content\/uploads\/2023\/10\/springer.png",250,200,false],"2048x2048":["https:\/\/ucthp.hospitalelcalafate.gob.ar\/wp-content\/uploads\/2023\/10\/springer.png",250,200,false]},"uagb_author_info":{"display_name":"Mirtha","author_link":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?author=2"},"uagb_comment_info":0,"uagb_excerpt":"Martina Jablo\u00f1ski, Mar\u00eda Sol Rodr\u00edguez,\u00a0Ezequiel Mariano Rivero,\u00a0Carlos David Bruque,\u00a0Silvia Vanzulli,\u00a0Ariana Bruzzone,\u00a0Cecilia P\u00e9rez Pi\u00f1ero,\u00a0Isabel Alicia L\u00fcthy Abstract Purpose:&nbsp;Globally breast cancer accounts for 24.5% in incidence and 15.5% in cancer deaths in women. The triple-negative subtype lacks any specific therapy and is treated with chemotherapy, resulting in significant side-effects. We aimed to investigate if the dose of&hellip;","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/ucthp.hospitalelcalafate.gob.ar\/?cat=11\" class=\"advgb-post-tax-term\">publicaciones<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">publicaciones<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Publicado 3 a\u00f1os hace","modified":"Actualizado 2 a\u00f1os hace"},"absolute_dates":{"created":"Publicado el 19 de septiembre de 2023","modified":"Actualizado el 3 de noviembre de 2023"},"absolute_dates_time":{"created":"Publicado el 19 de septiembre de 2023 2:31 pm","modified":"Actualizado el 3 de noviembre de 2023 2:36 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/index.php?rest_route=\/wp\/v2\/posts\/581","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=581"}],"version-history":[{"count":2,"href":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/index.php?rest_route=\/wp\/v2\/posts\/581\/revisions"}],"predecessor-version":[{"id":583,"href":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/index.php?rest_route=\/wp\/v2\/posts\/581\/revisions\/583"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/index.php?rest_route=\/wp\/v2\/media\/518"}],"wp:attachment":[{"href":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=581"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=581"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ucthp.hospitalelcalafate.gob.ar\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=581"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}